Difference between revisions of "Cytarabine and daunorubicin liposomal (Vyxeos)"
Jump to navigation
Jump to search
m (Text replacement - "[[Media:" to "[[File:") |
m (Text replacement - "[[File:" to "[[:File:") |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | This drug is a liposomal formulation of [[Cytarabine (Ara-C)]] and [[Daunorubicin (Cerubidine)]] in a 5:1 molar ratio. <ref name="insert">[http://pp.jazzpharma.com/pi/vyxeos.en.USPI.pdf Cytarabine and daunorubicin liposomal (Vyxeos) package insert]</ref><ref>[[File:Daunorubicincytarabineliposomal.pdf | Cytarabine and daunorubicin liposomal (Vyxeos) package insert (locally hosted backup)]]</ref><ref>[https://vyxeos.com/ Vyxeos manufacturer's website]</ref> | + | This drug is a liposomal formulation of [[Cytarabine (Ara-C)]] and [[Daunorubicin (Cerubidine)]] in a 5:1 molar ratio. <ref name="insert">[http://pp.jazzpharma.com/pi/vyxeos.en.USPI.pdf Cytarabine and daunorubicin liposomal (Vyxeos) package insert]</ref><ref>[[:File:Daunorubicincytarabineliposomal.pdf | Cytarabine and daunorubicin liposomal (Vyxeos) package insert (locally hosted backup)]]</ref><ref>[https://vyxeos.com/ Vyxeos manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
Revision as of 03:38, 20 September 2021
Mechanism of action
This drug is a liposomal formulation of Cytarabine (Ara-C) and Daunorubicin (Cerubidine) in a 5:1 molar ratio. [1][2][3]
Route: IV
Extravasation: no information
Disease for which it is used
History of changes in FDA indication
- 8/3/2017: Granted FDA regular approval for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis. (Based on CLTR0310-301)
Patient Information
Also known as
- Code name: CPX-351
- Brand name: Vyxeos